ReviewFrontiers in psychiatry2026
Precision phenotyping of elevated arousal in posttraumatic stress disorder: implications for personalized GABAergic pharmacotherapy.
Review in Frontiers in psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Posttraumatic stress disorder (PTSD) is a common and disabling condition, and current first-line medications have remission rates as low as 20-30%. Novel agents targeting the GABAergic system offer a promising alternative approach to treatment given converging evidence for a central role for this system in PTSD pathophysiology. However, overall progress in PTSD psychopharmacology has been hampered by the substantial heterogeneity in this population, which has been highlighted by recent research on both subjective symptoms and underlying biological mechanisms. In this mini review, we examine the literature on heterogeneity in PTSD, particularly with respect to anxious arousal. We examine heterogeneity in arousal based on both clinical symptoms and objective behavioral or biological markers. We also examine evidence for a specific role for GABAergic dysfunction in causing elevated anxious arousal. These lines of research suggest that novel GABAergic agents may be particularly effective in a high arousal PTSD subgroup. Future research should incorporate individual subjective and objective measures of anxious arousal into clinical trials of GABAergic agents for PTSD, with the ultimate aim of developing personalized treatments for selected individuals within this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.